ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder ce… Read more
ReproCELL Incorporated (6RC) - Total Liabilities
Latest total liabilities as of September 2025: €688.22 Million EUR
Based on the latest financial reports, ReproCELL Incorporated (6RC) has total liabilities worth €688.22 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ReproCELL Incorporated - Total Liabilities Trend (2014–2025)
This chart illustrates how ReproCELL Incorporated's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ReproCELL Incorporated Competitors by Total Liabilities
The table below lists competitors of ReproCELL Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
USA | $2.99 Million |
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
USA | $76.29 Million |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
Finland | €413.00 Million |
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
Thailand | ฿2.56 Billion |
|
Kernel Holding SA
F:0KE
|
Germany | €1.23 Billion |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
China | CN¥8.06 Billion |
|
Alterity Therapeutics Ltd
NASDAQ:ATHE
|
USA | $2.65 Million |
|
Sappe Public Company Limited
BK:SAPPE
|
Thailand | ฿1.10 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down ReproCELL Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ReproCELL Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ReproCELL Incorporated (2014–2025)
The table below shows the annual total liabilities of ReproCELL Incorporated from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €685.81 Million | -7.45% |
| 2024-03-31 | €741.03 Million | -5.07% |
| 2023-03-31 | €780.62 Million | -7.57% |
| 2022-03-31 | €844.53 Million | +28.65% |
| 2021-03-31 | €656.43 Million | +32.64% |
| 2020-03-31 | €494.89 Million | +18.16% |
| 2019-03-31 | €418.85 Million | +19.88% |
| 2018-03-31 | €349.38 Million | -28.05% |
| 2017-03-31 | €485.60 Million | -30.73% |
| 2016-03-31 | €701.00 Million | +37.45% |
| 2015-03-31 | €510.00 Million | +127.68% |
| 2014-03-31 | €224.00 Million | -- |